NCT06233942

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 308 (estimated)
• Sponsor: BeOne Medicines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	BG-C9074	administered by intravenous infusion
DRUG	Tislelizumab	administered by intravenous infusion
DRUG	Bevacizumab	administered by intravenous infusion

Timeline

• Start date: 2024-04-12
• Primary completion: 2027-09-28
• Completion: 2028-05-15
• First posted: 2024-01-31
• Last updated: 2026-04-15

Locations

38 sites across 5 countries: United States, Australia, Brazil, China, Japan

Regulatory

• FDA-regulated drug study